Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, Parren PWHI, Taylor RP.

Haematologica. 2019 Feb 21. pii: haematol.2018.207266. doi: 10.3324/haematol.2018.207266. [Epub ahead of print]

2.

Critical role of C5a in sickle cell disease.

Vercellotti GM, Dalmasso AP, Schaid TR Jr, Nguyen J, Chen C, Ericson ME, Abdulla F, Killeen T, Lindorfer MA, Taylor RP, Belcher JD.

Am J Hematol. 2019 Mar;94(3):327-337. doi: 10.1002/ajh.25384. Epub 2019 Jan 3.

PMID:
30569594
3.

Mechanisms of Complement-Mediated Damage in Hematological Disorders.

Taylor RP, Lindorfer MA.

Semin Hematol. 2018 Jul;55(3):118-123. doi: 10.1053/j.seminhematol.2018.02.003. Epub 2018 Feb 14. Review.

PMID:
30032747
4.

Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease.

Jalal D, Renner B, Laskowski J, Stites E, Cooper J, Valente K, You Z, Perrenoud L, Le Quintrec M, Muhamed I, Christians U, Klawitter J, Lindorfer MA, Taylor RP, Holers VM, Thurman JM.

J Am Heart Assoc. 2018 Jul 13;7(14). pii: e007818. doi: 10.1161/JAHA.117.007818.

5.

Corrigendum: IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.

Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G.

Nat Immunol. 2017 Sep 19;18(10):1173. doi: 10.1038/ni1017-1173c. No abstract available.

PMID:
28926542
6.

Complement C5a-Induced Changes in Neutrophil Morphology During Inflammation.

Denk S, Taylor RP, Wiegner R, Cook EM, Lindorfer MA, Pfeiffer K, Paschke S, Eiseler T, Weiss M, Barth E, Lambris JD, Kalbitz M, Martin T, Barth H, Messerer DAC, Gebhard F, Huber-Lang MS.

Scand J Immunol. 2017 Sep;86(3):143-155. doi: 10.1111/sji.12580.

7.

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.

Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G.

Nat Immunol. 2017 Aug;18(8):889-898. doi: 10.1038/ni.3770. Epub 2017 Jun 12. Erratum in: Nat Immunol. 2017 Sep 19;18(10 ):1173.

8.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Morgan BP.

Clin Immunol. 2017 Aug;181:24-28. doi: 10.1016/j.clim.2017.05.016. Epub 2017 May 31.

9.

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP.

Clin Immunol. 2016 Oct;171:32-35. doi: 10.1016/j.clim.2016.08.017. Epub 2016 Aug 18.

10.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP.

J Immunol. 2016 Sep 1;197(5):1762-75. doi: 10.4049/jimmunol.1600648. Epub 2016 Jul 29.

11.

Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.

Taylor RP, Lindorfer MA.

Semin Immunol. 2016 Jun;28(3):309-16. doi: 10.1016/j.smim.2016.03.003. Epub 2016 Mar 19. Review.

PMID:
27009480
12.

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.

Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, de Jong RN, Beurskens FJ, Schuurman J, Parren PW, Taylor RP.

Mol Immunol. 2016 Feb;70:13-23. doi: 10.1016/j.molimm.2015.12.007. Epub 2015 Dec 12.

PMID:
26690706
13.

Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.

van den Bremer ET, Beurskens FJ, Voorhorst M, Engelberts PJ, de Jong RN, van der Boom BG, Cook EM, Lindorfer MA, Taylor RP, van Berkel PH, Parren PW.

MAbs. 2015;7(4):672-80. doi: 10.1080/19420862.2015.1046665.

14.

Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.

Taylor RP, Lindorfer MA.

Blood. 2015 Jan 29;125(5):762-6. doi: 10.1182/blood-2014-10-569244. Epub 2014 Dec 10. Review.

15.

Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies.

Taylor RP, Lindorfer MA.

Mol Pharmacol. 2014 Nov;86(5):485-91. doi: 10.1124/mol.114.092684. Epub 2014 Jun 18. Review.

16.

A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.

Paixão-Cavalcante D, Torreira E, Lindorfer MA, Rodriguez de Cordoba S, Morgan BP, Taylor RP, Llorca O, Harris CL.

J Immunol. 2014 May 15;192(10):4844-51. doi: 10.4049/jimmunol.1303131. Epub 2014 Apr 11.

17.

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.

Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE.

Am J Hematol. 2014 Jul;89(7):757-65. doi: 10.1002/ajh.23737. Epub 2014 Apr 26.

18.

Complement is activated by IgG hexamers assembled at the cell surface.

Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW.

Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943.

19.

Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pettinger AM, Shanafelt TD, Nowakowski GS, Zent CS.

J Immunol. 2014 Feb 15;192(4):1620-9. doi: 10.4049/jimmunol.1302954. Epub 2014 Jan 15.

20.

Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.

Sharma R, Zhao H, Al-Saleem FH, Ubaid AS, Puligedda RD, Segan AT, Lindorfer MA, Bermudez R, Elias M, Adekar SP, Simpson LL, Taylor RP, Dessain SK.

Mol Immunol. 2014 Feb;57(2):247-54. doi: 10.1016/j.molimm.2013.09.005. Epub 2013 Nov 1.

21.

Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.

Pokrass MJ, Liu MF, Lindorfer MA, Taylor RP.

Mol Immunol. 2013 Dec;56(4):549-60. doi: 10.1016/j.molimm.2013.05.242. Epub 2013 Aug 1.

PMID:
23911412
22.

The role of complement in mAb-based therapies of cancer.

Taylor RP, Lindorfer MA.

Methods. 2014 Jan 1;65(1):18-27. doi: 10.1016/j.ymeth.2013.07.027. Epub 2013 Jul 22. Review.

PMID:
23886909
23.

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.

Mo CC, Njuguna N, Beum PV, Lindorfer MA, Vire B, Lee E, Marti G, Wilson WH, Taylor RP, Wiestner A.

Haematologica. 2013 Aug;98(8):1259-63. doi: 10.3324/haematol.2012.080929. Epub 2013 May 28.

24.

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Lindorfer MA, Wiestner A, Zent CS, Taylor RP.

Oncoimmunology. 2012 Sep 1;1(6):959-961.

25.

Anti-CD20 antibody therapy for B-cell lymphomas.

Taylor RP, Lindorfer MA, Zent CS.

N Engl J Med. 2012 Aug 30;367(9):876-7; author reply 878. doi: 10.1056/NEJMc1207378. No abstract available.

PMID:
22931338
26.

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.

Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath CJ, Fridkis-Hareli M, Selleri C, Lindorfer MA, Taylor RP, Luzzatto L, Holers VM.

Blood. 2012 Jun 28;119(26):6307-16. doi: 10.1182/blood-2011-12-398792. Epub 2012 May 10.

27.

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.

Baig NA, Taylor RP, Lindorfer MA, Church AK, Laplant BR, Pavey ES, Nowakowski GS, Zent CS.

Leuk Lymphoma. 2012 Nov;53(11):2218-27. doi: 10.3109/10428194.2012.681657. Epub 2012 May 21.

28.

Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.

Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP.

J Immunol. 2012 Apr 1;188(7):3532-41. doi: 10.4049/jimmunol.1103693. Epub 2012 Feb 24.

29.

Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.

Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PW, van de Winkel JG, Taylor RP.

J Immunol. 2011 Sep 15;187(6):3438-47. doi: 10.4049/jimmunol.1101189. Epub 2011 Aug 12.

30.

Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.

Beum PV, Lindorfer MA, Peek EM, Stukenberg PT, de Weers M, Beurskens FJ, Parren PW, van de Winkel JG, Taylor RP.

Eur J Immunol. 2011 Aug;41(8):2436-46. doi: 10.1002/eji.201041204. Epub 2011 Jul 4.

31.

Antigenic modulation and rituximab resistance.

Taylor RP, Lindorfer MA.

Semin Hematol. 2010 Apr;47(2):124-32. doi: 10.1053/j.seminhematol.2010.01.006. Review.

32.

The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell.

Daubeuf S, Lindorfer MA, Taylor RP, Joly E, Hudrisier D.

J Immunol. 2010 Feb 15;184(4):1897-908. doi: 10.4049/jimmunol.0901570. Epub 2010 Jan 20.

33.

A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.

Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ.

Blood. 2010 Mar 18;115(11):2283-91. doi: 10.1182/blood-2009-09-244285. Epub 2010 Jan 12.

34.

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.

Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP, Wiestner A.

Haematologica. 2010 Feb;95(2):329-32. doi: 10.3324/haematol.2009.012484. Epub 2009 Aug 13.

35.

Impact of low-dose rituximab on splenic B cells: evidence for the shaving reaction.

Taylor RP, Lindorfer MA.

Transpl Int. 2010 Jan;23(1):116-7. doi: 10.1111/j.1432-2277.2009.00913.x. Epub 2009 Jul 16. No abstract available.

36.

Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.

Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW, Taylor RP.

J Immunol. 2009 Jul 1;183(1):749-58. doi: 10.4049/jimmunol.0900632. Epub 2009 Jun 17.

37.

Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.

Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP.

J Immunol. 2008 Dec 1;181(11):8120-32.

39.

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

Taylor RP, Lindorfer MA.

Curr Opin Immunol. 2008 Aug;20(4):444-9. doi: 10.1016/j.coi.2008.05.011. Epub 2008 Jul 1. Review.

40.

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, Parren PW, van de Winkel JG, Taylor RP.

J Immunol. 2008 Jul 1;181(1):822-32.

41.

Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?

D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA.

Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):62-8. Review.

PMID:
18393924
43.

Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.

Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP.

J Immunol. 2007 Sep 15;179(6):4263-71.

44.

Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.

Taylor RP, Lindorfer MA.

Nat Clin Pract Rheumatol. 2007 Feb;3(2):86-95. Review.

PMID:
17299446
45.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Eggleton JC, Taylor RP.

J Immunol. 2006 Nov 15;177(10):7435-43.

46.

Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer.

Beum PV, Lindorfer MA, Hall BE, George TC, Frost K, Morrissey PJ, Taylor RP.

J Immunol Methods. 2006 Dec 20;317(1-2):90-9. Epub 2006 Oct 10.

PMID:
17067631
47.

Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys.

Whipple EC, Ditto AH, Shanahan RS, Gatesman JJ, Little SF, Taylor RP, Lindorfer MA.

Mol Immunol. 2007 Jan;44(4):377-88. Epub 2006 May 2.

PMID:
16631928
48.
49.

Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.

DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP.

Mol Immunol. 2006 Mar;43(7):1010-9. Epub 2005 Jun 14.

PMID:
15961157
50.

Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages.

Gyimesi E, Bankovich AJ, Schuman TA, Goldberg JB, Lindorfer MA, Taylor RP.

Immunol Lett. 2004 Sep;95(2):185-92.

PMID:
15388259

Supplemental Content

Loading ...
Support Center